Autologous Conditioned Plasma: Using Your Own Blood to Support Healing

Sarah sat in the exam room, rubbing her knee as the orthopedist reviewed her scans. Years of running and weekend hikes had left the joint stiff and swollen most mornings. Pain relievers helped for a while, but the ache returned. The doctor mentioned a treatment that uses a small sample of her own blood to support healing. She listened, curious about how something so familiar could target the problem directly.

What if the key to easing joint discomfort already sits in our veins, ready to be concentrated and put to work?

Autologous conditioned plasma, often shortened to ACP, is a preparation made from a patient’s own blood. The process isolates plasma rich in platelets and the growth factors they release. These components play a role in clotting and tissue repair. Unlike some other blood-derived products, ACP systems aim for a leukocyte-poor concentrate, which some clinicians prefer to reduce inflammation at the injection site.

The approach belongs to the broader category of orthobiologics, treatments that harness the body’s own materials rather than introducing foreign substances. Clinics worldwide offer it for musculoskeletal complaints, from professional athletes to active adults dealing with everyday wear.

Preparation happens in the office or procedure room and usually takes under thirty minutes. A clinician draws a modest amount of blood, typically fifteen milliliters for the standard double-syringe kit. The sample goes into a closed system that spins in a centrifuge for about five minutes. The spinning separates the components so the upper layer of plasma, now carrying a higher density of platelets, can be drawn off and readied for injection.

The same syringe design keeps everything sterile and contained until the moment of use. No additional chemicals or additives enter the mix in many protocols. The resulting fluid is then guided by ultrasound or landmark technique into the target tissue, such as a knee joint or a tendon attachment.

Photo by Alina Prokudina on Unsplash

Clinicians most often discuss ACP for early to moderate knee osteoarthritis. Patients report reduced pain and better daily function in some cases, though results vary. The same preparation finds use in tendon problems like lateral epicondylitis or Achilles tendinopathy, and occasionally in muscle strains or ligament support after injury. Veterinary practices apply similar techniques for companion animals with joint issues.

One concrete example comes from sports medicine settings where a runner with persistent patellar tendon pain receives a series of injections spaced a week or two apart. Follow-up care often includes physical therapy to rebuild strength while the biological signals from the platelets do their work.

Research offers a mixed but informative picture. A randomized, double-blind, placebo-controlled trial published in 2016 examined intra-articular ACP injections for knee osteoarthritis and found measurable improvements in pain scores and function with no reported adverse events. View the study abstract. Later work, including a 2023 analysis of patients with knee osteoarthritis, noted more modest gains and advised caution before routine clinical adoption.

A 2025 cohort study tracked outcomes and identified certain cellular characteristics in the prepared plasma that correlated with stronger responses at the six-month mark. These findings suggest future refinements in patient selection or processing could improve consistency. Overall, the safety profile remains favorable because the material comes from the individual receiving it.

Anyone considering the treatment meets with a physician to review medical history, imaging, and prior interventions. The procedure itself involves little downtime, though mild soreness at the injection site can last a day or two. Multiple sessions, often three spaced weekly, appear in many protocols. Insurance coverage differs by region and indication, so cost discussions form part of the planning conversation.

ACP differs from standard platelet-rich plasma in the specific collection hardware and the emphasis on a single-spin, low-white-cell output. Both fall under regenerative injection therapies, yet the exact formulation matters to some practitioners.

Photo by Mark Williams on Unsplash

Systems continue to evolve. Newer double-spin devices allow larger blood volumes and higher platelet concentrations while maintaining the closed, point-of-care workflow. Learn more about one widely used platform. Patients and clinicians alike watch for longer-term data that clarify which subgroups benefit most and how these injections fit alongside exercise, weight management, and other conservative measures.

Back in the exam room, Sarah left with printed information and a follow-up appointment. Her story is one of many that illustrate how a straightforward blood-based option sits among today’s choices for joint and soft-tissue care.